This article is more than 5 years old. Information may no longer be current.
Sibling, unrelated-donor HSCT conferred similar survival in DLBCL
Patients with diffuse large B-cell lymphoma who received matched sibling hematopoietic stem cell transplantation experienced similar outcomes to those who underwent unrelated donor transplantation, according to results of a retrospective analysis.
Researchers reviewed data on patients with DLBCL who underwent allogeneic HSCT from a matched sibling (n=301) or an unrelated donor (n=172). Median follow-up was 45 months.
At 3 years, PFS was 35% in both arms. OS was 42% for those who received matched-sibling allogenic HSCT vs. 37% for unrelated donor transplant.
Results of multivariate analysis indicated there were no associations between donor type and non-relapse mortality, relapse rate, PFS or OS.
However, PFS and OS were adversely affected by poor performance status and refractory disease. Those who previously underwent an HSCT and underwent multiple prior therapies were more likely to experience poorer PFS.
Older age, poor performance status and refractory disease adversely affected nonrelapse mortality. The relapse rate was adversely affected by a time from diagnosis to HSCT of less than 36 months, having a prior HSCT, refractory disease, poor performance status and in vivo T-cell depletion with alemtuzumab (Lemtrada, Genzyme).
Disclosure: See the full study for a list of the researchers’ relevant financial disclosures.